Accuray (ARAY) Reports Encouraging Breast Cancer Study Results
Accuray Incorporated ARAY recently published promising data from a prospective Phase II trial involving 338 women with low-risk breast cancer. Data from the study showed that 98.8% of women had local disease control after receiving accelerated partial breast irradiation (APBI) once daily with the TomoTherapy system after seven years.
Additionally, the study, which was also published online, indicated that the once-daily schedule was linked to a very low incidence of acute and late toxicities.
In particular, the TomoTherapy platform which includes the new generation Radixact system is the first platform in the world capable of delivering helical radiation. The platform offers precision that allows clinicians to deliver hypofractionated regimens like APBI with much more confidence.
This development is expected to give Accuray’s TomoTherapy platform a boost, which accounted for approximately 85% of unit revenue volume in the first quarter of fiscal 2021.
More on the news
It should be mentioned here that breast conserving surgery and APBI have been widely used in clinical practice for the treatment of low risk breast cancer over the past 10 years. The Accuray trial provides improvements over existing techniques, providing better APBI results in carefully selected patient groups.
The system has enabled healthcare teams to achieve exceptional long-term results through improved accuracy, making APBI an efficient and convenient option for patients.
In particular, this study takes into account existing clinical evidence, which shows the benefits of the TomoTherapy system in the treatment of breast cancer.
According to a report by MarketsandMarkets, the global radiation therapy market was valued at $ 5.6 billion in 2018 and is expected to experience a CAGR of 4.1% by 2023. Rising cancer incidence, awareness and the growing acceptance of radiotherapy and technological advancements are driving the market.
This month, Accuray announced the receipt of 510 (k) clearance for its ClearRT Helical kVCT imaging for the Radixact treatment delivery system from the FDA. This latest development is expected to expand the company’s next-generation TomoTherapy line-up and address the untapped radiotherapy market.
Similar to Accuray, few other companies in the broader medical field have recently published positive study results.
In December 2020, Medtronic plc MDT announced the publication of favorable results in the first batch of 100 patients who were treated with the OsteoCool Radiofrequency Ablation System (“RFA”) in the OPuS One clinical study. In particular, the company affirms that this study, which is the largest prospective study in RFA for bone metastases, is to date the most significant clinical data for the OsteoCool technology.
The same month, Pacific Biosciences of California, Inc. The PACB has published the first results of the company’s research partnership with LabCorp LH regarding SARS-CoV-2 and the immune response associated with COVID-19. The collaboration, which was announced in April 2020, has enabled these two companies to develop a production-scale assay for full genome sequencing of thousands of SARS-CoV-2 viruses. This was done on the basis of samples from positive patients anonymized using the PacBio Sequel II system.
Just Released: The 7 Best Zacks Actions For Today
Experts pulled 7 stocks from the 220 Zacks Rank # 1 Strong Buys list which beat the market more than 2 times more with an astonishing average gain of + 24.4% per year.
These 7 were selected because of their greater potential for immediate rupture.
See these time sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report